Did Lilly Overcome US Price Pressures In Last Quarter? Investors Await Answer
Executive Summary
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
You may also be interested in...
Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D
Revealing that the pegylated IL-10 therapy acquired in the Armo buyout two years ago has failed a pair of Phase II NSCLC trials, Lilly said it plans no further studies with the drug. Trulicity and Taltz led Lilly’s continuing growth story.
Two Mega-Mergers Were Just The Highlights Of A Year Of Major Deals
BMS/Celgene and AbbVie/Allergan were the biggest biopharma deals by dollar value in 2019, and the third and seventh largest ever. The year saw 23 deals valued at $1bn or more, including 20 M&A agreements.
Lilly Adds Two More Humalog Authorized Generics As Insurance Deductibles Reset
With rebate reform efforts stalled, insulin manufacturer broadens efforts to lower prices through authorized generics, but PBMs may still like the big rebates they can get on the original brands.